BeOne Medicines **Corporate Overview**

BeOne is a global oncology company driven by scientific excellence and exceptional speed to reach more patients than ever before.

From the beginning, we set out to defy the status quo and reimagine how life-changing cancer therapies are discovered, developed, and delivered to the people who need them. Our in-house, end-to-end ecosystem spanning research, development, manufacturing, and commercialization enables us to move with speed and precision from idea to impact.

Our integrated model has delivered innovative, internally discovered medicines that are transforming standards of care worldwide: BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab).

Today, we operate in more than **40 markets** across **six continents**. **With approximately 2 million patients** already treated with our medicines worldwide, we're just getting started.

United by science, driven by purpose

Our R&D approach is bold by design and driven by a singular mission: **to discover and develop transformative therapies for patients with exceptional speed.**

- One of the industry's most prolific and promising pipelines, with more than 40 clinical and commercial-stage assets targeting high-burden cancers, including blood, lung, breast/ gynecological, gastrointestinal, and rare cancers.
- One of the largest oncology-dedicated research teams in the world, with almost 5,000 scientists, clinicians, and innovators.



For more information visit:

BeOneMedicines.com **@BeOneMedicines** **@BeOneMeds**

BeOne

Facts at a Glance

~12k
Colleagues globally in over **40** offices on **6** continents

$3.8B
2024 total revenue*

~2M
Patients treated with our medicines

40+
Assets in clinical and commercial stages

1.2k+
Oncology research team

3.8k+
global clinical development & medical affairs team members

In-house manufacturing
including diversified global supply chain

40+
Phase 3 or potentially registration enabling trials

*As of November 2025

Global Capabilities to Reach More Patients

From agile manufacturing to strategic partnerships, we are building the infrastructure and alliances to deliver transformative cancer therapies around the world – faster, reliably, and at scale.

Agile manufacturing for global resilience

Our integrated internal manufacturing capabilities are designed for speed, quality, and resilience with facilities strategically located to ensure uninterrupted access for patients worldwide.

Partnering for impact

Cancer is too complex to solve alone, and we have partnerships with 75+ patients and advocacy organizations living with cancer around the world to better understand the cancer journey, and close gaps in education, diagnosis, and improve access.

We have collaborated with health systems in almost 60 countries to accelerate the availability of our medicines because we know patients are waiting.

As we work towards achieving our mission, our focus on sustainable practices improves operational resilience and safeguards business continuity.



Opened in 2024, the Princeton West Innovation Campus in New Jersey, United States houses a state-of-the art, clinical and commercial-stage biologics manufacturing facility and clinical R&D center, to complement our existing capabilities around the world.

For more information visit:

BeOneMedicines.com **@BeOneMedicines** **@BeOneMeds**

BeOne